TORC vs. TRVI, PYXS, XBIT, ME, STTK, ABEO, GLSI, VTYX, GTHX, and MCRB
Should you be buying resTORbio stock or one of its competitors? The main competitors of resTORbio include Trevi Therapeutics (TRVI), Pyxis Oncology (PYXS), XBiotech (XBIT), 23andMe (ME), Shattuck Labs (STTK), Abeona Therapeutics (ABEO), Greenwich LifeSciences (GLSI), Ventyx Biosciences (VTYX), G1 Therapeutics (GTHX), and Seres Therapeutics (MCRB). These companies are all part of the "medical" sector.
resTORbio (NASDAQ:TORC) and Trevi Therapeutics (NASDAQ:TRVI) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, community ranking, analyst recommendations, profitability, media sentiment, valuation, institutional ownership, earnings and dividends.
46.2% of resTORbio shares are owned by institutional investors. Comparatively, 95.8% of Trevi Therapeutics shares are owned by institutional investors. 11.8% of resTORbio shares are owned by company insiders. Comparatively, 24.4% of Trevi Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
In the previous week, Trevi Therapeutics had 3 more articles in the media than resTORbio. MarketBeat recorded 3 mentions for Trevi Therapeutics and 0 mentions for resTORbio. Trevi Therapeutics' average media sentiment score of 0.30 beat resTORbio's score of 0.00 indicating that Trevi Therapeutics is being referred to more favorably in the news media.
Trevi Therapeutics has a consensus target price of $8.00, indicating a potential upside of 146.15%. Given Trevi Therapeutics' higher possible upside, analysts clearly believe Trevi Therapeutics is more favorable than resTORbio.
resTORbio has a beta of 2.43, indicating that its share price is 143% more volatile than the S&P 500. Comparatively, Trevi Therapeutics has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.
Trevi Therapeutics' return on equity of -39.54% beat resTORbio's return on equity.
Trevi Therapeutics is trading at a lower price-to-earnings ratio than resTORbio, indicating that it is currently the more affordable of the two stocks.
resTORbio received 62 more outperform votes than Trevi Therapeutics when rated by MarketBeat users. Likewise, 67.14% of users gave resTORbio an outperform vote while only 61.24% of users gave Trevi Therapeutics an outperform vote.
Summary
Trevi Therapeutics beats resTORbio on 10 of the 14 factors compared between the two stocks.
Get resTORbio News Delivered to You Automatically
Sign up to receive the latest news and ratings for TORC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TORC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
resTORbio Competitors List
Related Companies and Tools
